Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors

Gemcitabine based treatment is currently a standard first line treatment for patients with advanced pancreatic cancer, however overall survival remains poor, and few options are available for patients that fail gemcitabine based therapy. To identify potential molecular targets in gemcitabine refract...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Biol Ther
Главные авторы: Samulitis, Betty K, Pond, Kelvin W, Pond, Erika, Cress, Anne E, Patel, Hitendra, Wisner, Lee, Patel, Charmi, Dorr, Robert T, Landowski, Terry H
Формат: Artigo
Язык:Inglês
Опубликовано: Taylor & Francis 2014
Предметы:
Research Papers
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4623403/
https://ncbi.nlm.nih.gov/pubmed/25485960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/15384047.2014.986967
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы